PIM3 Kinase: A Promising Novel Target in Solid Cancers

Pinar Atalay, Bulent Ozpolat

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


PIM3 (provirus-integrating Moloney site 3) is a serine/threonine kinase and belongs to the PIM family (PIM1, PIM2, and PIM3). PIM3 is a proto-oncogene that is frequently overexpressed in cancers originating from endoderm-derived tissues, such as the liver, pancreas, colon, stomach, prostate, and breast cancer. PIM3 plays a critical role in activating multiple oncogenic signaling pathways promoting cancer cell proliferation, survival, invasion, tumor growth, metastasis, and progression, as well as chemo- and radiation therapy resistance and immunosuppressive microenvironment. Genetic inhibition of PIM3 expression suppresses in vitro cell proliferation and in vivo tumor growth and metastasis in mice with solid cancers, indicating that PIM3 is a potential therapeutic target. Although several pan-PIM inhibitors entered phase I clinical trials in hematological cancers, there are currently no FDA-approved inhibitors for the treatment of patients. This review provides an overview of recent developments and insights into the role of PIM3 in various cancers and its potential as a novel molecular target for cancer therapy. We also discuss the current status of PIM-targeted therapies in clinical trials.

Original languageEnglish (US)
Article number535
Issue number3
StatePublished - Jan 26 2024


  • PIM kinase inhibitors
  • PIM3
  • serine/threonine kinase
  • solid cancer
  • targeted therapies
  • triple-negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'PIM3 Kinase: A Promising Novel Target in Solid Cancers'. Together they form a unique fingerprint.

Cite this